Company
Headquarters: West Vancouver, BC, Canada
Employees: 5
CEO: Dr. William V. Williams M.D.
C$168.7 Million
CAD as of Dec. 1, 2021
US$131.7 Million
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $309.91 B |
Vertex Pharmaceuticals Incorporated | $117.36 B |
CSL Limited | $95.75 B |
Regeneron Pharmaceuticals, Inc. | $59.14 B |
Marinomed Biotech AG | $58.56 B |
Company | Market Cap (USD) |
---|---|
Lilly | $699.59 B |
Johnson & Johnson | $374.29 B |
AbbVie | $336.94 B |
Novo Nordisk | $309.91 B |
UnitedHealth Group | $279.90 B |
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
BriaCell Therapeutics Corp has the following listings and related stock indices.
Stock: TSXV: BCT wb_incandescent
Stock: NASDAQ: BCTX wb_incandescent